Novocure to Report Fourth Quarter and Full Year 2016 Financial Results
January 10 2017 - 7:00AM
Business Wire
Novocure (NASDAQ:NVCR) announced today that it will report
financial results for the fourth quarter and full year 2016 on
Thursday, Feb. 23, 2017, before the open of U.S.-based financial
markets. Novocure management will host a conference call and
webcast to discuss its financial results for the three and 12
months ended Dec. 31, 2016, at 8 a.m. EST on Thursday, Feb. 23,
2017.
Analysts and investors can participate in the conference call by
dialing 877-726-5929 for domestic callers and 530-379-4648 for
international callers, using the conference ID 47566930. The
webcast can be accessed live from the Investor Relations page of
Novocure’s website, www.novocure.com/investor-relations, and will
be available for replay for at least 14 days following the
call.
About Novocure
Novocure is a commercial-stage oncology company developing a
novel, proprietary therapy called Tumor Treating Fields, or
TTFields, for the treatment of solid tumor cancers. Novocure’s
commercialized product, Optune, is approved for the treatment of
adult patients with glioblastoma. Novocure has ongoing or completed
phase 2 pilot trials investigating TTFields in non-small cell lung
cancer, pancreatic cancer, ovarian cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in
Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York
City. Additionally, the company has offices in Germany, Switzerland
and Japan, and a research center in Haifa, Israel. For additional
information about the company, please visit www.novocure.com or
follow us at www.twitter.com/novocure.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170110005464/en/
Media and Investors:NovocureAshley Cordova,
212-767-7558acordova@novocure.com
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Mar 2024 to Apr 2024
NovoCure (NASDAQ:NVCR)
Historical Stock Chart
From Apr 2023 to Apr 2024